Results 211 to 220 of about 8,234,457 (404)

Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population

, 2018
Sławomir Jeka, Bogdan Batko, Mariusz Korkosz, Maria Majdan, Brygida Kwiatkowska, Iwona Dankiewicz-Fares, Jerzy Maciej Sobiecki, Włodzimierz Samborski   +7 more
openalex   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Efficacy and Safety of Cell-Based Therapies for Drug-Resistant Epilepsy: A Systematic Review of Human Studies

Ziaee, Arash, Arshia Khalesi, Toosi, Mehran Beiraghi, Akhondian, Javad, Alireza Khalesi, Amirali Latifian   +5 more
openalex   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Management of adverse events in TB care and active TB drug safety monitoring. [PDF]

Breathe (Sheff)
Ma'aruf SY, Sharma A, Fox S, Duarte R, Lange C, Tiberi S.   +5 more
europepmc   +1 more source

Legislation and drug safety [PDF]

Journal of Clinical Pathology, 1975
openaire   +3 more sources

Understanding the pharmacology and toxicology properties of transdermal buprenorphine and fentanyl to ensure the safety and efficacy of drugs use [PDF]

, 2018
Christina Yuen Ki Leung
openalex  

Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment outcomes, Cellular Uptake, Safety and Immunomodulatory Potential [PDF]

Malik Saim Jameel, Alveena Mushtaq Malik
openalex   +1 more source

Role of Prednisone and 25‐Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi, Andrea Fava, Daniel W. Goldman, Laurence S. Magder, Michelle Petri   +4 more
wiley   +1 more source

Role of Pharmacovigilance in Drug Safety Monitoring. [PDF]

Indian Dermatol Online J
Paul AE, Sasidharanpillai S.
europepmc   +1 more source